Radiofrequency ablation for thyroid nodules — Coverage criteria
Customize your policy alerts
Sign up for all husky_health policy alerts
Know when husky_health releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity, prior authorization, and coverage criteria for radiofrequency ablation (RFA) of thyroid nodules for HUSKY Health (Connecticut Medicaid) providers.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
inv-01: Medically Necessary Indications
Radiofrequency ablation is considered medically necessary when ONE of the following distinct groups is met:
From policy section A; applies to benign nodules
From policy section B; limited burden nodal recurrence only
inv-02: Not Medically Necessary / Experimental
Considered experimental, investigational, or unproven and therefore not medically necessary.
Coverage for radiofrequency ablation (RFA) of the thyroid is limited to the specific clinical indications and criteria listed in this policy. RFA is considered medically necessary only when one of the covered groups is met: A) Benign thyroid nodules meeting all listed criteria (high surgical risk, symptomatic, and cytology confirming non‑malignancy) or B) locoregional recurrent differentiated thyroid cancer with limited nodal burden. Requests that do not meet these conditions will be evaluated as not medically necessary. Authorization decisions reflect medical necessity at the time of review and do not guarantee payment; payment depends on active coverage and benefits at the time of service.
Any thyroid RFA indication other than the two explicitly listed in this policy (A: benign thyroid nodules meeting all stated criteria or B: locoregional recurrent differentiated thyroid cancer with limited burden nodal disease) is considered experimental, investigational, or unproven and is not medically necessary.
Billing Codes and Coding Guidance
| 60660 | Ablation of one or more thyroid nodule(s), one lobe or the isthmus, percutaneous, including imaging guidance, radiofrequency. |
| 60661 | Ablation of one or more thyroid nodule(s), additional lobe, percutaneous, with imaging guidance, radiofrequency [list separately in addition to code for primary service] |
| 20982 | RFA treatment of tumors metastasized to distant sites (example code listed as not requiring prior authorization in this policy context). |
| 32998 | RFA treatment of tumors metastasized to distant sites (example code listed as not requiring prior authorization in this policy context). |
| 47380 | RFA treatment of tumors metastasized to distant sites (example code listed as not requiring prior authorization in this policy context). |
| 47382 | RFA treatment of tumors metastasized to distant sites (example code listed as not requiring prior authorization in this policy context). |
Authorization, Documentation, and Provider Requirements
Prior authorization required for thyroid RFA CPT codes
Prior authorization is required for CPT codes 60660 and 60661 for percutaneous radiofrequency ablation of thyroid nodule(s). Submit an authorization request before performing services billed with these codes.
- 60660: Ablation of one or more thyroid nodule(s), one lobe or the isthmus, percutaneous, including imaging guidance, radiofrequency.
- 60661: Ablation of one or more thyroid nodule(s), additional lobe, percutaneous, with imaging guidance, radiofrequency (list separately in addition to code for primary service).
Action: Confirm indication and clinical rationale
Ensure the service and diagnosis match the policy’s covered indications before requesting authorization; clarify the clinical rationale and prior surgeries or treatments when applicable to expedite review.
- Confirm whether the indication meets covered categories (A: benign nodules meeting all criteria; B: locoregional recurrent differentiated thyroid cancer with limited nodal burden).
- Provide history of why surgery is high-risk or prior treatment details to support necessity.
Required documentation for authorization requests
Submit a fully completed authorization request through the online web portal and include supporting documentation from the requesting physician demonstrating medical necessity.
- Fully completed authorization request via online web portal.
- Documentation from the requesting physician supporting medical necessity (e.g., clinical notes, fine needle aspiration results, surgical risk assessment).
Non-covered indications may be denied
Requests for RFA that do not meet the policy’s stated medical necessity criteria may be denied as experimental, investigational, or not medically necessary.
- Non-covered thyroid indications (any thyroid RFA not explicitly listed under A or B) are considered not medically necessary and may be denied.
- Authorization is based on medical necessity at the time issued and is not a guarantee of payment.
Background
Radiofrequency ablation (RFA) is a minimally invasive, image‑guided procedure that uses a percutaneously inserted electrode to deliver thermal energy to targeted thyroid nodule tissue, producing coagulative necrosis and subsequent reduction in nodule volume. In this policy context RFA is described as an alternative to surgery or radioactive iodine for treatment of benign nodules or for limited locoregional recurrent differentiated thyroid cancer when surgery may be high risk or undesirable.
Definitions and Special Provisions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.